Abstract:The analysis of serum endogenous peptides holds promise for disease study and drug discovery, whereas it is relatively unexplored given its challenges in analysis reproducibility and reliability. Here, we developed a streamlined detection platform for high-sensitive and reproducible serum peptidome profiling by data-independent acquisition (DIA) strategy. Compared to the classic data-dependent acquisition (DDA), our developed DIA approach can quantify almost twice the number of peptides with half the median coefficients of variation detected for DDA. The platform enables reproducible profiling of thousands of peptides and their post-translational modifications after simple sample preparation. The developed platform was subsequently utilized in the serum peptidome study of clear-cell renal cell carcinoma (ccRCC). A total of 31 ccRCC patients and 31 healthy volunteers were enrolled. Significant differences in serum peptidome patterns were observed between the two groups, allowing us to distinguish ccRCC patients from healthy volunteers clearly. A total of 833 modified peptides were found significantly changed in the ccRCC patients. The study demonstrated the high potential of serum peptidome in cancer detection and the feasibility and advantage of applying the DIA-based platform on large-scale serum peptidomic analysis for biomarker discovery. SIGNIFICANCE: Serum peptidomic study proves to be challenging given its low abundance and instability of endogenous peptides. In this study, we developed a fast, reproducible and accurate detection platform by DIA-based MS method for streamlined serum peptidome profiling. The developed platform was then utilized in the serum peptidome study of ccRCC. To our knowledge, this is the first report to apply DIA strategy to disease related peptidomic studies. The large difference in serum peptidome profiles enabled us to distinguish ccRCC patients from healthy volunteers clearly, illuminating the great potential of serum peptidome in cancer diagnosis. The discovered significantly changed peptides provided a better understanding of the pathophysiological changes in ccRCC.

LC-MS based serum metabonomic analysis for renal cell carcinoma diagnosis, staging, and biomarker discovery.

Dysregulated Serum Metabolites in Staging of Hepatocellular Carcinoma.

LC-MS-based serum metabolic profiling for genitourinary cancer classification and cancer type-specific biomarker discovery.

Study on potential markers for diagnosis of renal cell carcinoma by serum untargeted metabolomics based on UPLC-MS/MS

Largescale Multicenter Study of a Serum Metabolite Biomarker Panel for the Diagnosis of Breast Cancer

Metabonomic profiling of renal cell carcinoma: high-resolution proton nuclear magnetic resonance spectroscopy of human serum with multivariate data analysis.

Liquid Chromatography-Mass Spectrometry Based Serum Peptidomic Approach for Renal Clear Cell Carcinoma Diagnosis

Serum and Urine Metabolic Fingerprints Characterize Renal Cell Carcinoma for Classification, Early Diagnosis, and Prognosis

Application of SELDI-TOF-MS to identify serum biomarkers for renal cell carcinoma.

RRLC-MS/MS-based metabonomics combined with in-depth analysis of metabolic correlation network: finding potential biomarkers for breast cancer.

Application of ex vivo 1 H NMR metabonomics to the characterization and possible detection of renal cell carcinoma metastases

Metabolomics in renal cell carcinoma: From biomarker identification to pathomechanism insights

Direct infusion mass spectrometry or liquid chromatography mass spectrometry for human metabonomics? A serum metabonomic study of kidney cancer.

LC–MS-based serum metabolomics analysis for the screening and monitoring of colorectal cancer

Integrated ionization approach for RRLC-MS/MS-based metabonomics: finding potential biomarkers for lung cancer.

Identification of Potential Serum Proteomic Biomarkers for Clear Cell Renal Cell Carcinoma

Global metabolomics reveals potential urinary biomarkers of esophageal squamous cell carcinoma for diagnosis and staging

Advancing Serum Peptidomic Profiling by Data-Independent Acquisition for Clear-Cell Renal Cell Carcinoma Detection and Biomarker Discovery.

Prediction and diagnosis of renal cell carcinoma using nuclear magnetic resonance-based serum metabolomics and self-organizing maps.

POD-06.01: Early and Noninvasive Diagnosis of Renal Cell Carcinoma Using 1H-Nmr-based Metabonomics

Identification of serum biomarkers of hepatocarcinoma through liquid chromatography/mass spectrometry-based metabonomic method